• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Selph S, Dana T, et al. Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov. (Evidence Syntheses, No. 95.)

Cover of Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation

Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet].

Show details

REFERENCES

1.
Chou R, Huffman L. Screening for Human Immunodeficiency Virus: Focused Update of a 2005 Systematic Evidence Review for the U.S. Preventive Services Task Force, Evidence Synthesis No. 46. Rockville, MD: Agency for Healthcare Research and Quality; Apr, 2007. [24 October 2012]. AHRQ Publication No. 07-0597-EF-1. Accessed at http://www​.ncbi.nlm.nih​.gov/books/NBK33475/ on. [PubMed: 20722143]
2.
Chou R, Korthuis PT, Huffman LH, Smits AK. Screening for Human Immunodeficiency Virus in Adolescents and Adults, Evidence Synthesis No. 38. Rockville, MD: Agency for Healthcare Reseach and Quality; Jul, 2005. [24 October 2012]. Accessed at http://www​.ahrq.gov/downloads​/pub/prevent/pdfser/hivrevsyn​.pdf on.
3.
Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT. U.S. Preventive Services Task Force. Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143(1):55–73. [PubMed: 15998755]
4.
U.S. Preventive Services Task Force. Screening for HIV: Recommendation Statement. Rockville, MD: Agency for Healthcare Reseach and Quality; Jul, 2005. AHRQ Publication No. 07-0597-EF-2. (Amended April 2007)
5.
Chou R, Smits AK, Huffman LH, Korthuis PT. Screening for Human Immunodeficiency Virus in Pregnant Women, Evidence Synthesis No. 39. Rockville, MD: Agency for Healthcare Research and Quality; Jul, 2005. [24 October 2012]. Accessed at http://www​.ncbi.nlm.nih​.gov/books/NBK33383/ on.
6.
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Centers for Disease Prevention and Control. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17. [PubMed: 16988643]
7.
Peterman TA, Todd KA, Mupanduki I. Opportunities for targeting publicly funded human immunodeficinecy virus counseling and testing. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(1):69–74. [PubMed: 8624764]
8.
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95. [PubMed: 15703423]
9.
Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85. [PubMed: 15703422]
10.
Centers for Disease Control and Prevention. HIV-2 surveillance—United States, 1987–2009. MMWR Morb Mortal Wkly Rep. 2011;60(29):985–8. [PubMed: 21796096]
11.
Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1–19. [PubMed: 1361652]
12.
Centers for Disease Control and Prevention. HIV in the United States: At a Glance. Atlanta: Centers for Disease Control and Prevention; 2012. [24 October 2012]. Accessed at http://www​.cdc.gov/hiv​/resources/factsheets/us.htm on.
13.
Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR Morb Mortal Wkly Rep. 2011;60(21):689–93. [PubMed: 21637182]
14.
Campsmith ML, Rhodes PH, Hall I, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53(5):619–24. [PubMed: 19838124]
15.
Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502. [PMC free article: PMC3149556] [PubMed: 21826193]
16.
Centers for Disease Control and Prevention. Increases in HIV diagnoses—29 states, 1999–2002. MMWR Morb Mortal Wkly Rep. 2003;52(47):1145–8. [PubMed: 14647015]
17.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2006. Atlanta: Centers for Disease Control and Prevention; 2008. [24 October 2012]. Accessed at http://www​.cdc.gov/hiv​/topics/surveillance​/resources/reports​/2006report/pdf/2006SurveillanceReport​.pdf on.
18.
Centers for Disease Control and Prevention. Persons Living With a Diagnosis of HIV Infection, by Year and Selected Characteristics, 2006–2008: 40 States With Confidential Name-Based HIV Infection Reporting. Atlanta: Centers for Disease Control and Prevention; 2009. [24 October 2012]. Accessed at http://www​.cdc.gov/hiv​/surveillance/resources​/reports/2009report/pdf/table15a​.pdf on.
19.
Quinn TC, Wawer MJ, Sewankambo NK, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9. [PubMed: 10738050]
20.
Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149–53. [PubMed: 11323041]
21.
Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000;14(6):717–26. [PubMed: 10807195]
22.
Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33–9. [PubMed: 9647878]
23.
Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125(4):257–64. [PubMed: 8678387]
24.
Vanhems P, Allard R, Cooper DA, Perrin L, Vizzard J, Hirschel B, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive? Clin Infect Dis. 1997;24(5):965–70. [PubMed: 9142802]
25.
Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324(14):961–4. [PubMed: 1823118]
26.
Henrard DR, Phillips JF, Muenz LR, Blattner WA, Wiesner D, Eyster ME, et al. Natural history of HIV-1 cell-free viremia. JAMA. 1995;274(7):554–8. [PubMed: 7629984]
27.
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123–6. [PubMed: 7816094]
28.
Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med. 1998;128(8):613–20. [PubMed: 9537934]
29.
Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, et al. CASCADE Collaboration. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS. 2004;18(12):1697–705. [PubMed: 15280781]
30.
Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373(6510):117–22. [PubMed: 7529365]
31.
Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet. 2000;355(9210):1131–7. [PubMed: 10791375]
32.
Koblin B, van Benthem BH, Buchbinder SP, Ren L, Vittinghoff E, Stevens CE, et al. Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978–1995. Am J Epidemiol. 1999;150(10):1026–30. [PubMed: 10568617]
33.
Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992;165(2):352–63. [PubMed: 1346152]
34.
Kaslow RA, Phair JP, Friedman HB, Lyter D, Solomon RE, Dudley J, et al. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann Intern Med. 1987;107(4):474–80. [PubMed: 2957944]
35.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al. UK Collaborative HIV Cohort Study. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21(13):1717–21. [PubMed: 17690569]
36.
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al. ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–29. [PubMed: 12126821]
37.
Phillips A, Pezzotti P., CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS. 2004;18(1):51–8. [PubMed: 15090829]
38.
Phillips AN, Lee CA, Elford J, Janossy G, Timms A, Bofill M, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet. 1991;337(8738):389–92. [PubMed: 1671424]
39.
Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122(8):573–9. [PubMed: 7887550]
40.
Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–54. [PubMed: 9182471]
41.
Phair JP, Mellors JW, Detels R, Margolick JB, Muñoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS. 2002;16(18):2455–9. [PubMed: 12461420]
42.
Babiker AG, Peto T, Porter K, Walker AS, Darbyshire JH. Age as a determinant of survival in HIV infection. J Clin Epidemiol. 2001;54(Suppl 1):S16–21. [PubMed: 11750205]
43.
Vella S, Giuliano M, Floridia M, Chiesi A, Tomino C, Seeber A, et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS. 1995;9(1):51–6. [PubMed: 7893441]
44.
Pedersen C, Lindhardt BO, Jensen BL, Lauritzen E, Gerstoft J, Dickmeiss E, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. 1989;299(6692):154–7. [PMC free article: PMC1837064] [PubMed: 2569901]
45.
de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med. 1997;127(10):882–90. [PubMed: 9382366]
46.
Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al. International Meta-Analysis of HIV Host Genetics. Effects of CCR5-delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135(9):782–95. [PubMed: 11694103]
47.
Lathey JL, Tierney C, Chang SY, D'Aquila RT, Bettendorf DM, Alexander HC, et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis. 2001;184(11):1402–11. [PubMed: 11709782]
48.
Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, et al. HIV Network for Prevention Trials Vaccine Preparedness Protocol Team. Homozygous and heterozygous CCR5-delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr. 2001;27(5):472–81. [PubMed: 11511825]
49.
Nolan D, Gaudieri S, John M, Mallal S. Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground. AIDS. 2004;18(9):1231–40. [PubMed: 15362655]
50.
Centers for Disease Control and Prevention. Estimates of New HIV Infections in the United States. Atlanta: Centers for Disease Control and Prevention; 2008. [24 October 2012]. Accessed at http://www​.cdc.gov/nchhstp​/newsroom/docs​/Fact-Sheet-on-HIV-Estimates.pdf on.
51.
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447–50. [PubMed: 16791020]
52.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2012. [24 October 2012]. Accessed at http://www​.aidsinfo.nih​.gov/ContentFiles​/AdultandAdolescentGL.pdf on.
53.
McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW., Adult/Adolescent Spectrum of Disease Group. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS. 1999;13(13):1687–95. [PubMed: 10509570]
54.
Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H., Centers for Disease Control and Prevention. National Institutes of Health. HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207. [PubMed: 19357635]
55.
Centers for Disease Control. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. JAMA. 1989;262(24):3395–7. [PubMed: 2685380]
56.
Centers for Disease Control. Update: serologic testing for HIV-1 antibody—United States, 1988 and 1989. MMWR Morb Mortal Wkly Rep. 1990;39(22):380–3. [PubMed: 2111436]
57.
Lampe M, Branson B, Paul S, Burr C, Gross E, Eicher C, et al. Rapid HIV Antibody Testing During Labor and Delivery for Women of Unknown HIV Status: A Practical Guide and Model Protocol. Atlanta: Centers for Disease Control and Prevention; 2004. [24 October 2012]. Accessed at http://www​.cdc.gov/hiv​/topics/testing/resources​/guidelines/rt-labor&delivery.htm on.
58.
Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006;8(2):125–31. [PubMed: 16524549]
59.
Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S102–5. [PubMed: 21406978]
60.
Centers for Disease Control and Prevention. Vital signs: HIV testing and diagnosis among adults—United States, 2001–2009. MMWR Morb Mortal Wkly Rep. 2010;59(47):1550–5. [PubMed: 21124295]
61.
Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK., Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150(2):125–31. [PubMed: 19047022]
62.
Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, et al. HIV policy: the path forward—a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis. 2009;48(10):1335–44. [PubMed: 19385087]
63.
American College of Obstetricians and Gynecologists. ACOG Committee Opinion: routine human immunodeficiency virus screening. Obstet Gynecol. 2008;112(2 Pt 1):401–3. [PubMed: 18669743]
64.
Emmanuel PJ, Martinez J., Committee on Pediatric AIDS, American Academy of Pediatrics. Adolescents and HIV infection: the pediatrician's role in promoting routine testing. Pediatrics. 2011;128(5):1023–9. [PubMed: 22042816]
65.
American Academy of Family Physicians. Human Immunodeficiency Virus. Leawood, KS: American Academy of Family Physicians; 2005. [24 October 2012]. Accessed at http://www​.aafp.org/online​/en/home/clinical/exam/hiv.html on.
66.
Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Methods Work Group. Third U.S. Preventive Services Task Force. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35. [PubMed: 11306229]
67.
Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62(10):1013–20. [PubMed: 19230606]
68.
Haukoos JS, Hopkins E, Conroy AA, Silverman M, Byyny RL, Eisert S, et al. Denver Emergency Department HIV Opt-Out Study Group. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA. 2010;304(3):284–92. [PubMed: 20639562]
69.
Weis KE, Liese AD, Hussey J, Coleman J, Powell P, Gibson JJ, et al. A routine HIV screening program in a South Carolina community health center in an area of low HIV prevalence. AIDS Patient Care STDS. 2009;23(4):251–8. [PubMed: 19281345]
70.
Cunningham CO, Doran B, DeLuca J, Dyksterhouse R, Asgary R, Sacajiu G. Routine opt-out HIV testing in an urban community health center. Aids Patient Care STDS. 2009;23(8):619–23. [PMC free article: PMC2832648] [PubMed: 19591606]
71.
Centers for Disease Control and Prevention. Routinely recommended HIV testing at an urban urgent-care clinic—Atlanta, Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(25):538–41. [PubMed: 11446572]
72.
Haukoos JS, Hopkins E, Bender B, Al-Tayyib A, Long J, Harvey J, et al. Denver Emergency Department HIV Testing Research Consortium. Use of kiosks and patient understanding of opt-out and opt-in consent for rountine rapid human immunodeficiency virus screening in the emergency department. Acad Emerg Med. 2012;19(3):287–93. [PubMed: 22435861]
73.
White DA, Scribner AN, Vahidnia F, Dideum PJ, Gordon DM, Frazee BW, et al. HIV screening in an urban emergency department: comparison of screening using an opt-in versus an opt-out approach. Ann Emerg Med. 2011;58(Suppl 1):S89–95. [PubMed: 21684416]
74.
Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, et al. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med. 2008;23(6):800–7. [PMC free article: PMC2517869] [PubMed: 18421508]
75.
Bowles KE, Clark HA, Tai E, Sullivan PS, Song B, Tsang J, et al. Implementing rapid HIV testing in outreach and community settings: results from an advancing HIV prevention demonstration project conducted in seven U.S. cities. Public Health Rep. 2008;123(Suppl 3):78–85. [PMC free article: PMC2567007] [PubMed: 19172705]
76.
Myers JJ, Modica C, Dufour MS, Bernstein C, McNamara K. Routine rapid HIV screening in six community health centers serving populations at risk. J Gen Intern Med. 2009;24(12):1269–74. [PMC free article: PMC2787931] [PubMed: 19655204]
77.
Walensky RP, Reichmann WM, Arbelaez C, Wright E, Katz JN, Seage GR 3rd, et al. Counselor- versus provider-based HIV screening in the emergency department: results from the Universal Screening for HIV infection in the Emergency Room (USHER) randomized controlled trial. Ann Emerg Med. 2011;58(Suppl 1):S126–32. [PMC free article: PMC3268065] [PubMed: 21684391]
78.
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20. [PMC free article: PMC2862849] [PubMed: 20415573]
79.
District of Columbia HIV/AIDS, Hepatitis, STD, and TB Administration. Annual Report 2010. Washington, DC: Government of the District of Columbia, Department of Health; 2010. [24 October 2012]. Accessed at http://doh​.dc.gov/sites​/default/files/dc​/sites/doh/publication​/attachments/2010_Annual​_Report_FINAL_0.pdf on.
80.
Buchacz K, Armon C, Palella FJ, Baker RK, Tedaldi E, Durham MD, et al. CD4 cells counts at HIV diagnosis among HIV outpatient study participants, 2000–2009. AIDS Res Treat. 2012;2012:869841. [PMC free article: PMC3176626] [PubMed: 21941640]
81.
Centers for Disease Control and Prevention. Voluntary HIV testing as part of routine medical care—Massachusetts, 2002. MMWR Morb Mortal Wkly Rep. 2004;53(24):523–6. [PubMed: 15215739]
82.
Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446–53. [PubMed: 16010168]
83.
Weinhardt LS. HIV diagnosis and risk behavior. In: Kalichman SC, editor. Positive Prevention: Reducing HIV Transmission Among People Living With HIV/AIDS. New York: Kluwer Academic/Plenum; 2005.
84.
Amaro H, Morrill AC, Dai J, Cabral H, Raj A. Heterosexual behavioral maintenance and change following HIV counseling and testing. J Health Psychol. 2005;10(2):287–300. [PubMed: 15723897]
85.
Brogly SB, Bruneau J, Lamothe F, Vincelette J, Franco EL. HIV-positive notification and behavior changes in Montreal injection drug users. AIDS Educ Prev. 2002;14(1):17–28. [PubMed: 11900107]
86.
Camoni L, Regine V, Colucci A, Conte ID, Chiriotto M, Vullo V, et al. Changes in at-risk behavior for HIV infection among HIV-positive persons in Italy. AIDS Patient Care STDS. 2009;23(10):853–8. [PubMed: 19803694]
87.
Fox J, White PJ, Macdonald N, Weber J, McClure M, Fidler S, et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med. 2009;10(7):432–8. [PubMed: 19459996]
88.
Bruneau J, Lamothe F, Soto J, Lachance N, Vincelette J, Vassal A, et al. Sex-specific determinants of HIV infection among injection drug users in Montreal. Can Med Assoc J. 2001;164(6):767–73. [PMC free article: PMC80871] [PubMed: 11276542]
89.
Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA. 2004;292(2):224–36. [PubMed: 15249572]
90.
Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health. 2002;92(3):388–94. [PMC free article: PMC1447086] [PubMed: 11867317]
91.
Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet. 2001;357(9254):432–5. [PubMed: 11273063]
92.
Blair JM, Hanson DL, Jones JL, Dworkin MS. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol. 2004;103(4):663–8. [PubMed: 15051556]
93.
Del Romero J, Castilla J, Hernando V, Rodríguez C, García S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:c2205. [PMC free article: PMC2871073] [PubMed: 20472675]
94.
Diamond C, Richardson JL, Milam J, Stoyanoff S, McCutchan JA, Kemper C, et al. California Collaborative Trials Group. Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr. 2005;39(2):211–8. [PubMed: 15905739]
95.
Elford J, Ibrahim F, Bukutu C, Anderson J. Sexual behaviour of people living with HIV in London: implications for HIV transmission. AIDS. 2007;21(Suppl 1):S63–70. [PubMed: 17159590]
96.
Miguez-Burbano MJ, Pineda-Medina L, Lecusay R, Page JB, Castillo G, Burbano X, et al. Continued high risk behaviors in HIV infected drug abusers. J Addict Dis. 2002;21(4):67–80. [PubMed: 12296503]
97.
Morin SF, Myers JJ, Shade SB, Koester K, Maiorana A, Rose CD. Predicting HIV transmission risk among HIV-infected patients seen in clinical settings. AIDS Behav. 2007;11(5 Suppl):S6–16. [PubMed: 17577655]
98.
Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction. 2006;101(3):433–40. [PubMed: 16499516]
99.
Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis. 2004;38(8):1167–74. [PubMed: 15095224]
100.
Elford J, Anderson J, Bukutu C, Ibrahim F. HIV in East London: ethnicity, gender and risk. Design and methods. BMC Public Health. 2006;6(1):150. [PMC free article: PMC1524742] [PubMed: 16764715]
101.
van Haastrecht HJ, van den Hoek JA, Bardoux C, Leentvaar-Kuypers A, Coutinho RA. The course of the HIV epidemic among intravenous drug users in Amsterdam, The Netherlands. Am J Public Health. 1991;81(1):59–62. [PMC free article: PMC1404932] [PubMed: 1983918]
102.
Vlahov D, Anthony JC, Muñoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. J Drug Issues. 1991;21(4):759–76. [PubMed: 1661376]
103.
Vlahov D, Safaien M, Lai S, Strathdee SA, Johnson L, Sterling T, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS. 2001;15(17):2311–6. [PubMed: 11698705]
104.
Barroso PF, Schechter M, Gupta P, Melo MF, Vieira M, Murta FC, et al. Effect of antiretroviral therapy on HIV shedding in semen. Ann Intern Med. 2000;133(4):280–4. [PubMed: 10929169]
105.
Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14(4):415–21. [PubMed: 10770544]
106.
Operskalski EA, Stram DO, Busch MP, Huang W, Harris M, Dietrich SL, et al. Transfusion Safety Study Group. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Am J Epidemiol. 1997;146(8):655–61. [PubMed: 9345119]
107.
Musicco M, Lazzarin A, Nicolosi A, Gasparini M, Costigliola P, Arici C, et al. Italian Study Group on HIV Heterosexual Transmission. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Arch Intern Med. 1994;154(17):1971–6. [PubMed: 8074601]
108.
Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2011;(8):CD009153. [PubMed: 21833973]
109.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. [PMC free article: PMC3200068] [PubMed: 21767103]
110.
Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8. [PMC free article: PMC2922041] [PubMed: 20537376]
111.
Melo MG, Santos BR, De Cassia Lira R, Varella IS, Turella ML, Rocha TM, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, Southern Brazil. Sex Transm Dis. 2008;35(11):912–5. [PubMed: 18607309]
112.
Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011;25(4):473–7. [PMC free article: PMC3261071] [PubMed: 21160416]
113.
Sullivan P, Kayitenkore K, Chomba E, Karita E, Mwananyanda L, Vwalika C. Reduction of HIV transmission risk and high risk sex while prescribed ART: results from discordant couples in Rwanda and Zambia. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montréal, Canada.
114.
Wang L, Ge Z, Luo J, Duo S, Xing G, Guo-Wei D, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr. 2010;55(2):232–8. [PMC free article: PMC3058178] [PubMed: 21423851]
115.
Padian NS, O'Brien TR, Chang Y, Glass S, Francis DP. Prevention of heterosexual transmission of human immunodeficiency virus through couple conseling. J Acquir Immune Defic Syndr. 1993;6(9):1043–8. [PubMed: 8340895]
116.
NIMH Multisite HIV/STD Prevention Trial for African American Couples Group. Eban HIV/STD risk reduction intervention: conceptual basis and procedures. J Acquir Immune Defic Syndr. 2008;49(Suppl 1):S15–27. [PMC free article: PMC3274174] [PubMed: 18724186]
117.
El-Bassel N, Jemmott JB, Landis JR, Pequegnat W, Wingood GM, Wyatt GE, et al. NIMH Multisite HIV/STD Prevention Trial for African American Couples Group. National Institute of Mental Health multisite Eban HIV/STD prevention intervention for African American HIV serodiscordant couples: a cluster randomized trial. Arch Intern Med. 2010;170(17):1594–601. [PMC free article: PMC4011550] [PubMed: 20625011]
118.
Hernando V, del Romero J, García S, Rodríguez C, del Amo J, Castilla J. Reducing sexual risk behavior among steady heterosexual serodiscordant couples in a testing and counseling program. Sex Transm Dis. 2009;36(10):621–8. [PubMed: 19955873]
119.
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337(11):725–33. [PubMed: 9287227]
120.
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734–9. [PubMed: 9287228]
121.
Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351(9102):543–9. [PubMed: 9492772]
122.
Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001;15(17):2251–7. [PubMed: 11698698]
123.
Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77. [PubMed: 11722271]
124.
Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, et al. Adult/Adolescent Spectrum of HIV Disease Project Investigators. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/μL. Clin Infect Dis. 2003;37(7):951–8. [PubMed: 13130408]
125.
Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, et al. ICONA Study Group. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS. 2001;15(8):983–90. [PubMed: 11399980]
126.
Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138(8):620–6. [PubMed: 12693883]
127.
Ahdieh-Grant L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick JB, et al. When to initiate highly active antiretroviral therapy: a cohort approach. Am J Epidemiol. 2003;157(8):738–46. [PubMed: 12697578]
128.
Sterling TR, Chaisson RE, Moore RD. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis. 2003;36(6):812–5. [PubMed: 12627368]
129.
Opravil M, Ledergerber B, Furrer H, Hirschel B, Imhof A, Gallant S, et al. Swiss HIV Cohort Study. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count >350 × 106/L. AIDS. 2002;16(10):1371–81. [PubMed: 12131214]
130.
Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. New Engl J Med. 2010;363(3):257–65. [PMC free article: PMC3676927] [PubMed: 20647201]
131.
Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133–44. [PubMed: 18476292]
132.
Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med. 2011;171(17):1560–19. [PMC free article: PMC3960856] [PubMed: 21949165]
133.
Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, et al. HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154(8):509–15. [PMC free article: PMC3610527] [PubMed: 21502648]
134.
Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, et al. HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24(1):123–37. [PMC free article: PMC2920287] [PubMed: 19770621]
135.
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26. [PMC free article: PMC2854555] [PubMed: 19339714]
136.
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, et al. Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185–97. [PMC free article: PMC3460385] [PubMed: 17502729]
137.
Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352–63. [PMC free article: PMC2670965] [PubMed: 19361855]
138.
El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96. [PubMed: 17135583]
139.
Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, et al. Antiretroviral Therapy Cohort Collaboration. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009;23(16):2199–208. [PMC free article: PMC3122149] [PubMed: 19779320]
140.
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, et al. Antiretroviral Therapy Cohort Collaboration. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr. 2009;52(3):357–63. [PMC free article: PMC3032437] [PubMed: 19668084]
141.
Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003. [PubMed: 14627784]
142.
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–35. [PubMed: 17460226]
143.
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417–26. [PMC free article: PMC2688660] [PubMed: 18387667]
144.
Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs study. J Infect Dis. 2010;201(3):318–30. [PubMed: 20039804]
145.
Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84–91. [PubMed: 21653308]
146.
Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11(2):130–6. [PubMed: 19682101]
147.
Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52(7):929–40. [PMC free article: PMC3062545] [PubMed: 21427402]
148.
Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sørensen HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol. 2008;38(5):1202–6. [PubMed: 18799495]
149.
Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, et al. Virological control during the first 6–18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Clin Infect Dis. 2006;42(1):136–44. [PubMed: 16323104]
150.
Fiore JR, Zhang YJ, Björndal A, Di Stefano M, Angarano G, Pastore G, et al. Biological correlates of HIV-1 heterosexual transmission. AIDS. 1997;11(9):1089–94. [PubMed: 9233454]
151.
Lee TH, Sakahara N, Fiebig E, Busch MP, O'Brien TR, Herman SA. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(4):427–8. [PubMed: 8673554]
152.
Pedraza MA, del Romero J, Roldán F, García S, Ayerbe MC, Noriega AR, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr. 1999;21(2):120–5. [PubMed: 10360803]
153.
Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(1):42–5. [PubMed: 9436757]
154.
Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr. 2002;29(3):275–83. [PubMed: 11873077]
155.
Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses. 2001;17(10):901–10. [PMC free article: PMC2748905] [PubMed: 11461676]
156.
Fisher M, Pao D, Brown AE, Sudarshi D, Gill ON, Cane P, et al. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS. 2010;24(11):1739–47. [PubMed: 20588173]
157.
Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5(6):e11068. [PMC free article: PMC2883572] [PubMed: 20548786]
158.
Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9. [PMC free article: PMC2996043] [PubMed: 20638713]
159.
Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649. [PMC free article: PMC2675696] [PubMed: 19406887]
160.
Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1):CD003255. [PubMed: 11869658]
161.
Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 1997;44(9):1303–12. [PubMed: 9141163]
162.
Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403–9. [PubMed: 15809897]
163.
Holtgrave DR. Costs and consequences of the U.S. Centers for Disease Control and Prevention's recommendations for opt-out HIV testing. PLoS Med. 2007;4(6):e194. [PMC free article: PMC1891318] [PubMed: 17564488]
164.
Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making. 2005;25(3):321–9. [PubMed: 15951459]
165.
Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889–903. [PMC free article: PMC3428219] [PubMed: 18559840]
166.
Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25(6):556–63. [PMC free article: PMC2869414] [PubMed: 20204538]
167.
Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797–806. [PubMed: 17146064]
168.
Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778–89. [PMC free article: PMC3173812] [PubMed: 21173412]
169.
Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825–31. [PubMed: 22301411]
170.
Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract. 2007;61(6):999–1014. [PubMed: 17504362]
171.
Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7. [PMC free article: PMC3483949] [PubMed: 22515871]
172.
NCT00867048: Strategic Timing of Antiretroviral Treatment (START) Bethesda, MD: National Institutes of Health; 2012. [24 October 2012]. Accessed at http:​//clinicaltrials​.gov/ct2/show/NCT00867048 on.
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.8M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...